Could a drug speed recovery from Guillain-Barré syndrome?
NCT ID NCT04752566
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial tested the drug eculizumab in 57 people with severe Guillain-Barré syndrome (GBS), a rare nerve disorder that can cause paralysis. Participants received either eculizumab or a placebo once a week for four weeks, alongside standard treatment. The study measured how quickly they regained the ability to walk and run. Results from this completed Japanese study may show whether eculizumab helps speed recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eculizumab (Soliris)
- What this could lead to
- If successful, eculizumab could offer a new treatment option to help people with severe Guillain-Barré syndrome recover faster and regain mobility.
- What could go wrong
- This is a small, completed Phase 3 trial in Japan only, so results may not apply broadly. Eculizumab carries risks like increased susceptibility to infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GUILLAIN-BARRE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Bunkyō City, 113-8519, Japan
-
Research Site
Chiba, 260-0877, Japan
-
Research Site
Fukuoka, 814-0180, Japan
-
Research Site
Hiroshima, 730-8518, Japan
-
Research Site
Kagoshima, 890-8520, Japan
-
Research Site
Kawagoe-shi, 350-8550, Japan
-
Research Site
Kawasaki-shi, 216-8511, Japan
-
Research Site
Kitakyushu-shi, 807-8555, Japan
-
Research Site
Kobe, 650-0047, Japan
-
Research Site
Kumamoto, 860-8556, Japan
-
Research Site
Kurashiki-shi, 710-8602, Japan
-
Research Site
Matsumoto-shi, 390-8621, Japan
-
Research Site
Mitaka-shi, 181-8611, Japan
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Niigata, 951-8520, Japan
-
Research Site
Nishinomiya-shi, 663-8501, Japan
-
Research Site
Sapporo, 060-8648, Japan
-
Research Site
Sayama, 589-8511, Japan
-
Research Site
Sendai, 983-8520, Japan
-
Research Site
Shimotsuga-gun, 321-0293, Japan
-
Research Site
Ube-shi, 755-8505, Japan
-
Research Site
Yokohama, 236-0004, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.